Antiandrogen Antineoplastic Adrenocortical Anti-Prostate Cancer Bicalutamide CAS 90357-06-5

Name:  Bicalutamide
CAS: 90357-06-5
MF: C18H14F4N2O4S
MW: 430.37
Bicaide Solubility: soluble in dimethyl formamide; dissolved in tetrahydrofuran; slightly soluble in ethyl acetate and methanol; insoluble in water.


 Bicaide tablets    

Bicalutamide tablet is a non-steroidal androgen antagonist, which competes androgen receptor with the androgen, blocks cellular uptake of androgen, and inhibits the binding of androgens to the target organ. It binds with the androgen receptor that forms receptor complex, which enters the nucleus and combined with the nucleoprotein, consequently inhibiting tumor cell growth. It can be as a first-line drug for palliative treatment of advanced prostate cancer. 


Dosage and administration:

Adult: adult males including the elderly: one (50mg), once a day. The treatment should be started simultaneously with LHRH analogue therapy or surgical orchiectomy.
Children: This product is contraindicated in children.

Renal impairment: The patients with renal impairment don't need dose adjustment.
Hepatic impairment: The patients with mild liver damage don't need dose adjustment, while the patients with severe liver damage may occur drug accumulation (see precautions).


Precautions:

This product is widely metabolized in the liver. Data show that patients with severe liver damage may slow down drug clearance, which may lead to accumulation. So the patients with moderate and severe liver injury should use it with caution.

The patients may appear liver changes by using it, so it should be considered regular liver function tests. The main changes generally appear within the first 6 months of treatment using this product.

Severe changes in liver function are rarely visible in the treatment of the product (see Adverse Reactions). If there is a serious change in treatment using this product, it should be discontinued.

This product is shown to inhibit the activity of cytochrome P450 (CYP3A4). When combined with drugs metabolised mainly by CYP3A4, the patients should be caution (see Contraindications and Drug Interactions).

Pregnancy and lactation: This product is contraindicated in women, especially for pregnant women or nursing mothers.

Effect on driving and operating machinery ability: This product does not affect the ability of patients of driving and operating the machine. 
 


 



Name:  Bicalutamide
CAS: 90357-06-5
MF: C18H14F4N2O4S
MW: 430.37
Bicaide Solubility: soluble in dimethyl formamide; dissolved in tetrahydrofuran; slightly soluble in ethyl acetate and methanol; insoluble in water.


 Bicaide tablets    

Bicalutamide tablet is a non-steroidal androgen antagonist, which competes androgen receptor with the androgen, blocks cellular uptake of androgen, and inhibits the binding of androgens to the target organ. It binds with the androgen receptor that forms receptor complex, which enters the nucleus and combined with the nucleoprotein, consequently inhibiting tumor cell growth. It can be as a first-line drug for palliative treatment of advanced prostate cancer. 


Dosage and administration:

Adult: adult males including the elderly: one (50mg), once a day. The treatment should be started simultaneously with LHRH analogue therapy or surgical orchiectomy.
Children: This product is contraindicated in children.

Renal impairment: The patients with renal impairment don't need dose adjustment.
Hepatic impairment: The patients with mild liver damage don't need dose adjustment, while the patients with severe liver damage may occur drug accumulation (see precautions).


Precautions:

This product is widely metabolized in the liver. Data show that patients with severe liver damage may slow down drug clearance, which may lead to accumulation. So the patients with moderate and severe liver injury should use it with caution.

The patients may appear liver changes by using it, so it should be considered regular liver function tests. The main changes generally appear within the first 6 months of treatment using this product.

Severe changes in liver function are rarely visible in the treatment of the product (see Adverse Reactions). If there is a serious change in treatment using this product, it should be discontinued.

This product is shown to inhibit the activity of cytochrome P450 (CYP3A4). When combined with drugs metabolised mainly by CYP3A4, the patients should be caution (see Contraindications and Drug Interactions).

Pregnancy and lactation: This product is contraindicated in women, especially for pregnant women or nursing mothers.

Effect on driving and operating machinery ability: This product does not affect the ability of patients of driving and operating the machine. 
 


 

NINGBO MEDICAL EQUIPMENT CO.,LTD , https://www.techartmeds.com